Navigation Links
Codexis R&D Productivity Panels Also Used By Roche
Date:5/12/2009

REDWOOD CITY, Calif., May 12 /PRNewswire/ -- Codexis, Inc. today announced an agreement with Roche under which Roche will purchase Codex(TM) Biocatalyst Panels, a biocatalysis-based research and manufacturing productivity product.

The Codex(TM) Panels are used by pharmaceutical manufacturers to increase manufacturing productivity while reducing cost. They are based on Codexis proprietary custom biocatalysts, which can accelerate production of human therapeutics through early development of faster, lower cost, cleaner manufacturing processes. They have been used by more than 10 pharmaceutical companies worldwide.

"We are very pleased that Roche, a world leading company, will use Codexis biocatalysis technology to enhance pharmaceutical process manufacturing productivity," said Peter Seufer-Wasserthal, Ph.D., Senior Vice President, Codexis Pharmaceuticals. "Since their introduction in 2007, the Codex(TM) panels have been used to generate first kilogram quantities of a target material in weeks, instead of months. Some processes have already advanced to commercial scale. Shorter development time can contribute to lower drug development costs over many years - a priority in tight economic times."

Biocatalysts enable development of environmentally-friendly, low cost methods to produce chirally pure chemicals and have already replaced chemocatalysts in certain processes. Codexis offers panels covering major classes of enzymes that can produce a broad range of chemicals widely used by the pharmaceutical industry.

Sets of diagnostic enzyme panels are provided in a convenient 96-well format to efficiently determine if a biocatalytic solution is available for a challenging process step in the production of active pharmaceutical ingredients and intermediates needed to produce human therapeutics. Panel data is then used to rapidly develop product-specific, customized biocatalysts and biocatalytic processes for Codexis' pharmaceutical partners.

Codexis Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit www.codexis.com.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis Names Lori Giver VP Systems Biology
2. Codexis, Teva in Licensing Agreement Final
3. Codexis Names Vice President, Intellectual Property
4. Codexis, Arch Announce Expanded Collaboration
5. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
6. Codexis Names David Anton VP Bioindustrials R&D
7. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
8. Rothwell, Wolf Elected to Codexis Board
9. Codexis Opens Singapore Laboratory
10. Bruce Pasternack Elected to Codexis Board
11. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... CA (PRWEB) , ... October 11, 2017 , ... ... upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding the ... system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... ... 10, 2017 , ... USDM Life Sciences , the ... sciences and healthcare industries, announces a presentation by Subbu Viswanathan and Jennifer Jaye ... GxP Validation for Agile Cloud Platforms,” will present a revolutionary approach to achieving ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):